Azenta, Inc. (AZTA) stock
Close on Nov 17, 2026Market cap $2.01BP/E –Yield –
Earnings
Azenta's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Azenta's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q1 FY2027ended Dec 31, 2026 | Feb 3, 2027Expected | – | – | – | – | – |
| Q4 FY2026ended Sep 30, 2026 | Nov 10, 2026after the close | $167.00M | +5.0% | $0.16 | $0.28 | Release |
| Q3 FY2026ended Jun 30, 2026 | Aug 4, 2026after the close | $161.00M | +11.8% | -$0.03 | $0.16 | Release |
| Q2 FY2026ended Mar 31, 2026 | May 5, 2026after the close | $145.00M | +1.4% | -$3.49 | -$0.04 | Release |
| Q1 FY2026ended Dec 31, 2025 | Feb 4, 2026before the open | $149.00M | +0.7% | -$0.11 | $0.09 | Release |
| Q4 FY2025ended Sep 30, 2025 | Nov 21, 2025before the open | $159.00M | -6.5% | $1.11 | $0.21 | Release |
| Q3 FY2025ended Jun 30, 2025 | Aug 5, 2025before the open | $144.00M | -16.8% | -$1.15 | $0.19 | Release |
| Q2 FY2025ended Mar 31, 2025 | May 7, 2025before the open | $143.00M | -10.1% | -$0.40 | $0.05 | Release |
| Q1 FY2025ended Dec 31, 2024 | Feb 5, 2025before the open | $148.00M | -3.9% | -$0.29 | $0.08 | Release |
| Q4 FY2024ended Sep 30, 2024 | Nov 12, 2024after the close | $170.00M | -1.2% | -$0.10 | $0.18 | Release |
| Q3 FY2024ended Jun 30, 2024 | Aug 6, 2024after the close | $173.00M | +4.2% | -$0.12 | $0.16 | Release |
| Q2 FY2024ended Mar 31, 2024 | May 8, 2024after the close | $159.00M | +7.4% | -$2.47 | $0.05 | Release |
| Q1 FY2024ended Dec 31, 2023 | Feb 7, 2024after the close | $154.00M | -13.5% | -$0.28 | $0.02 | Release |
| Q4 FY2023ended Sep 30, 2023 | Nov 13, 2023after the close | $172.00M | +24.6% | $0.06 | $0.13 | Release |
| Q3 FY2023ended Jun 30, 2023 | Aug 8, 2023after the close | $166.00M | +24.8% | -$0.02 | $0.13 | Release |
| Q2 FY2023ended Mar 31, 2023 | May 9, 2023after the close | $148.00M | +1.4% | -$0.07 | -$0.06 | Release |
| Q1 FY2023ended Dec 31, 2022 | Feb 8, 2023after the close | $178.00M | +27.1% | -$0.15 | $0.12 | Release |
| Q4 FY2022ended Sep 30, 2022 | Nov 14, 2022after the close | $138.00M | +0.7% | -$0.07 | $0.16 | Release |
| Q3 FY2022ended Jun 30, 2022 | Jul 13, 2022after the close | $133.00M | – | – | – | Release |
| Q2 FY2022ended Mar 31, 2022 | May 9, 2022after the close | $146.00M | – | -$0.02 | $0.12 | Release |
| Q1 FY2022ended Dec 31, 2021 | Feb 8, 2022after the close | $140.00M | – | $0.04 | $0.12 | Release |
| Q4 FY2021ended Sep 30, 2021 | Nov 10, 2021after the close | $137.00M | – | $0.29 | $0.78 | Release |
| Q3 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | – | Release |
| Q2 FY2021ended Mar 31, 2021 | May 10, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Dec 31, 2020 | Feb 2, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Sep 30, 2020 | Nov 10, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Azenta's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Total organic revenue growthnon-GAAP | Q1 FY2027 | +3% – +4% | – | New | Nov 10, 2026 |
| Adjusted EBITDA marginnon-GAAP | Q1 FY2027 | 100 – 150 | – | New | Nov 10, 2026 |
| Total organic revenue growthnon-GAAP | FY2027 | +3% – +5% | – | New | Nov 10, 2026 |
| total reported revenue from continuing operationsGAAP | FY2027 | $648.00M – $660.00M | – | New | Nov 10, 2026 |
| Adjusted EBITDA margin expansionnon-GAAP | FY2027 | 200 – 250 | – | New | Nov 10, 2026 |
| Free cash flownon-GAAP | FY2027 | +25% | – | New | Nov 10, 2026 |
Guidance vs results
The last range Azenta gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2026 | Revenue | $613.00M – $618.00M | $622.00MΣ4Q | Above range |
| Q4 FY2023 | EPS (GAAP) | -$0.20 – -$0.12 | $0.06 | Above range |
| Q4 FY2023 | Non-GAAP diluted earnings per share | -$0.02 – $0.06 | $0.13 | Above range |
| Q4 FY2023 | Revenue | $155.00M – $173.00M | $172.00M | Within range |
| Q3 FY2023 | EPS (GAAP) | -$0.29 – -$0.19 | -$0.02 | Above range |
| Q3 FY2023 | Non-GAAP diluted earnings per share | -$0.07 – $0.03 | $0.13 | Above range |
| Q3 FY2023 | Revenue | $150.00M – $168.00M | $166.00M | Within range |
| Q2 FY2023 | EPS (GAAP) | -$0.24 – -$0.16 | -$0.07 | Above range |
| Q2 FY2023 | non-GAAP diluted earnings per share | -$0.04 – $0.04 | -$0.06 | Below range |
| Q2 FY2023 | Revenue | $156.00M – $171.00M | $148.00M | Below range |
| Q1 FY2023 | EPS (GAAP) | -$0.20 – -$0.12 | -$0.15 | Within range |
| Q1 FY2023 | non-GAAP diluted earnings per share | $0.08 – $0.16 | $0.12 | Within range |
| Q1 FY2023 | Revenue | $175.00M – $190.00M | $178.00M | Within range |
| Q3 FY2022 | Revenue | $140.00M – $150.00M | $133.00M | Below range |
| Q2 FY2022 | EPS (GAAP) | -$0.04 – $0.04 | -$0.02 | Within range |
| Q2 FY2022 | non-GAAP diluted earnings per share | $0.07 – $0.15 | $0.12 | Within range |
| Q2 FY2022 | Revenue | $137.00M – $147.00M | $146.00M | Within range |
| Q1 FY2022 | EPS (GAAP) | -$0.14 – -$0.06 | $0.04 | Above range |
| Q1 FY2022 | Non-GAAP diluted earnings per share from continuing operations | $0.04 – $0.12 | $0.12 | Within range |
| Q1 FY2022 | Revenue | $130.00M – $140.00M | $140.00M | Within range |
Guidance history
Every forecast Azenta put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 10, 2026 | Adjusted EBITDA margin expansion | FY2027 | 200 – 250 | New |
| Nov 10, 2026 | Adjusted EBITDA margin | Q1 FY2027 | 100 – 150 | New |
| Nov 10, 2026 | Free cash flow | FY2027 | +25% | New |
| Nov 10, 2026 | total reported revenue from continuing operations | FY2027 | $648.00M – $660.00M | New |
| Nov 10, 2026 | Total organic revenue growth | FY2027 | +3% – +5% | New |
| Nov 10, 2026 | Total organic revenue growth | Q1 FY2027 | +3% – +4% | New |
| Aug 4, 2026 | Adjusted EBITDA | FY2026 | $59.00M – $62.00M | New |
| Aug 4, 2026 | Adjusted EBITDA | Q4 FY2026 | $20.00M – $23.00M | New |
| Aug 4, 2026 | Free cash flow | FY2026 | +10% – +15% | Reaffirmed |
| Aug 4, 2026 | total reported revenue from continuing operations | FY2026 | $613.00M – $618.00M | Narrowed |
| May 5, 2026 | Free Cash flow (cash flow from operations less capital expenditures) | FY2026 | +10% – +15% | New |
| May 5, 2026 | total reported revenue from continuing operations | FY2026 | $603.00M – $621.00M | New |
| May 5, 2026 | Total organic revenue | FY2026 | -2% – +1% | Lowered |
| Feb 4, 2026 | Total organic revenue | FY2026 | +3% – +5% | Reaffirmed |
| Nov 21, 2025 | Total organic revenue | FY2026 | +3% – +5% | New |
| Aug 5, 2025 | Adjusted EBITDA margin expansion | FY2025 | 300 | New |
| Aug 5, 2025 | Total organic revenue | FY2025 | +3% – +5% | New |
| May 7, 2025 | Total organic revenue | FY2025 | +3% – +5% | Reaffirmed |
| Feb 5, 2025 | Adjusted EBITDA margin expansion | FY2025 | 300 | Reaffirmed |
| Feb 5, 2025 | Total organic revenue | FY2025 | +3% – +5% | Reaffirmed |
| Nov 12, 2024 | Adjusted EBITDA margin expansion | FY2025 | 300 | New |
| Nov 12, 2024 | Total organic revenue | FY2025 | +3% – +5% | New |
| Aug 6, 2024 | Non-GAAP diluted earnings per share | FY2024 | $0.30 – $0.36 | Narrowed |
| Aug 6, 2024 | Adjusted EBITDA margin expansion | FY2024 | 300 | Reaffirmed |
| Aug 6, 2024 | Total organic revenue | FY2024 | -2% – -1% | Lowered |
| Aug 6, 2024 | Total revenue | FY2024 | $652.00M – $658.00M | Lowered |
| May 8, 2024 | Non-GAAP diluted earnings per share | FY2024 | $0.27 – $0.37 | Raised |
| May 8, 2024 | Adjusted EBITDA margin expansion | FY2024 | 300 | Reaffirmed |
| May 8, 2024 | Total revenue | FY2024 | $659.00M – $671.00M | Lowered |
| May 8, 2024 | Total organic revenue | FY2024 | -1% – +1% | Lowered |
| Feb 7, 2024 | Adjusted EBITDA margin expansion | FY2024 | 300 | New |
| Feb 7, 2024 | Non-GAAP diluted earnings per share | FY2024 | $0.19 – $0.29 | Reaffirmed |
| Feb 7, 2024 | Total revenue | FY2024 | $696.00M – $718.00M | New |
| Feb 7, 2024 | total organic revenue growth | FY2024 | +5% – +8% | Reaffirmed |
| Nov 13, 2023 | Non-GAAP diluted earnings per share | FY2024 | $0.19 – $0.29 | New |
| Nov 13, 2023 | Adjusted EBITDA margin expansion | FY2024 | 300 | New |
| Nov 13, 2023 | Total revenue | FY2024 | $696.00M – $718.00M | New |
| Nov 13, 2023 | total organic revenue growth | FY2024 | +5% – +8% | New |
| Aug 8, 2023 | Non-GAAP diluted earnings per share | Q4 FY2023 | -$0.02 – $0.06 | New |
| Aug 8, 2023 | GAAP diluted earnings per share from continuing operations | Q4 FY2023 | -$0.20 – -$0.12 | New |
| Aug 8, 2023 | Total revenue | Q4 FY2023 | $155.00M – $173.00M | New |
| Aug 8, 2023 | revenue | FY2023 | $648.00M – $665.00M | New |
| Aug 8, 2023 | Life Sciences Products revenue excluding B Medical | Q4 FY2023 | $45.00M – $55.00M | Lowered |
| Aug 8, 2023 | Life Sciences Services revenue | Q4 FY2023 | $86.00M – $94.00M | Lowered |
| Aug 8, 2023 | B Medical revenue | Q4 FY2023 | $24.00M | Lowered |
| May 9, 2023 | Non-GAAP diluted earnings per share | Q3 FY2023 | -$0.07 – $0.03 | New |
| May 9, 2023 | GAAP diluted earnings per share from continuing operations | Q3 FY2023 | -$0.29 – -$0.19 | New |
| May 9, 2023 | Total revenue | Q3 FY2023 | $150.00M – $168.00M | New |
| Feb 8, 2023 | non-GAAP diluted earnings per share | Q2 FY2023 | -$0.04 – $0.04 | New |
| Feb 8, 2023 | GAAP diluted earnings per share from continuing operations | Q2 FY2023 | -$0.24 – -$0.16 | New |
| Feb 8, 2023 | Revenue | Q2 FY2023 | $156.00M – $171.00M | New |
| Nov 14, 2022 | non-GAAP diluted earnings per share | Q1 FY2023 | $0.08 – $0.16 | New |
| Nov 14, 2022 | GAAP diluted earnings per share from continuing operations | Q1 FY2023 | -$0.20 – -$0.12 | New |
| Nov 14, 2022 | total revenue | FY2023 | +30% | New |
| Nov 14, 2022 | revenue | Q1 FY2023 | $175.00M – $190.00M | New |
| May 9, 2022 | non-GAAP diluted earnings per share | Q3 FY2022 | $0.09 – $0.17 | New |
| May 9, 2022 | GAAP diluted earnings per share from continuing operations | Q3 FY2022 | -$0.03 – $0.05 | New |
| May 9, 2022 | Revenue | Q3 FY2022 | $140.00M – $150.00M | New |
| Feb 8, 2022 | non-GAAP diluted earnings per share | Q2 FY2022 | $0.07 – $0.15 | New |
| Feb 8, 2022 | GAAP diluted earnings per share from continuing operations | Q2 FY2022 | -$0.04 – $0.04 | New |
| Feb 8, 2022 | Revenue | Q2 FY2022 | $137.00M – $147.00M | New |
| Nov 10, 2021 | Non-GAAP diluted earnings per share from continuing operations | Q1 FY2022 | $0.04 – $0.12 | New |
| Nov 10, 2021 | GAAP diluted loss per share | Q1 FY2022 | -$0.14 – -$0.06 | New |
| Nov 10, 2021 | Revenue | Q1 FY2022 | $130.00M – $140.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Azenta filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Update
- Results
- Update
- Update
- Results
- Update
- Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository CapabilitiesUpdate
- Results
- Update
- Update
- Update
- Results
See a number that looks wrong?